1.
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, rand...
by Sternberg, Cora N, Dr
The lancet oncology, 2015, Vol.16 (1), p.76-86
2.
Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled...
by Di Stasi, Savino M, Prof
The lancet oncology, 2011, Vol.12 (9), p.871-879
3.
Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy
by Hirasawa, Yosuke
Annals of surgical oncology, 2016, Vol.23 (Suppl 5), p.1048-1054
4.
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer
by Flores-Martín, José Francisco
Annals of surgical oncology, 2019, Vol.26 (8), p.2631-2639
5.
A novel fusion of HNRNPA1 – ALK in inflammatory myofibroblastic tumor of urinary bladder
by Inamura, Kentaro, MD, PhD
Human pathology, 2017, Vol.69, p.96-100
6.
The Prognostic Significance of the Early Postoperative Neutrophil-to-Lymphocyte Ratio in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy
by Kang, Minyong
Annals of surgical oncology, 2015, Vol.23 (1), p.335-342
7.
Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014
by Groeben, Christer
Annals of surgical oncology, 2018, Vol.25 (12), p.3502-3509
8.
Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling
by Wu, Chun-Te
Annals of surgical oncology, 2018, Vol.25 (12), p.3518-3526
9.
Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion
by Yoshida, Takefumi
Annals of surgical oncology, 2019, Vol.26 (5), p.1569-1576
10.
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma
by Zhong, Qiaofeng
Future oncology (London, England), 2021, Vol.17 (22), p.2893-2905
11.
Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the...
by May, Matthias
Annals of surgical oncology, 2011, Vol.18 (7), p.2018-2025
12.
FDG PET–CT for Lymph Node Staging of Bladder Cancer: A Prospective Study of Patients with Extended Pelvic Lymphadenectomy
by Jeong, In Gab
Annals of surgical oncology, 2015, Vol.22 (9), p.3150-3156
13.
14.
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy
by Karam, Jose A, MD
The lancet oncology, 2007, Vol.8 (2), p.128-136
15.
Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial
by Teoh, Jeremy Yuen-Chun
Annals of surgical oncology, 2016, Vol.24 (5), p.1428-1434
16.
Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis
by Vale, C
The Lancet (British edition), 2003, Vol.361 (9373), p.1927-1934
17.
18.
Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a...
by Ziegelmueller, Brigitte Katharina
Urologia internationalis, 2020, Vol.104 (1-2), p.55-61
19.
Neoadjuvant pembrolizumab in bladder cancer
by Gourd, Elizabeth
The lancet oncology, 2018, Vol.19 (12), p.e669-e669
20.
Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma
by Abdel-Rahman, Omar
Future oncology (London, England), 2019, Vol.15 (19), p.2267-2275
